In an early study, a tissue-engineered heart muscle product was linked to improvements in heart wall thickness, left ventricular ejection fraction and quality of life in patients with heart failure with reduced EF. Biologic ventricular assist tissue (Repairon) is “the first tissue-engineered heart muscle product in clinical trials” and the phase 1 to 2 BioVAT-HF study, published in